{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-359185","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2026-08-20T20:06:14+00:00","discovered_at":"2026-08-20T20:07:01.389014+00:00","generated_at":"2026-08-20T20:07:13.198710+00:00","sec_items":["1.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Werewolf sells pre-clinical INDUCER and INDUKINE platforms to EMD Serono for $28M upfront plus $5M","bullets":["Closed Aug 14, 2026 asset sale to EMD Serono: $28M upfront plus $5M upon transfer completion.","Sale covers pre-clinical INDUCER and INDUKINE platforms; excludes WTX-124 and WTX-330 clinical programs.","Company retains rights to advance WTX-124 and WTX-330; EMD grants exclusive license to related patents.","License agreement enables sublicenses to Harpoon and Jazz under existing agreements; 24-month non-compete."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-359185","json":"https://secwatch.observer/filing/0001193125-26-359185.json","markdown":"https://secwatch.observer/filing/0001193125-26-359185.md","text":"https://secwatch.observer/filing/0001193125-26-359185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000119312526359185/0001193125-26-359185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000119312526359185/d141219d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-20T20:07:13.198710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}